Medicare Coverage Of Tumor Assays Should Be Monitored - MCAC Panel
This article was originally published in The Gray Sheet
Executive Summary
Human tumor assay systems demonstrate clinical utility for certain patients and hold promise as a tool for treating a broad range of cancers, the Laboratory and Diagnostic Services Panel of the Medicare Coverage Advisory Committee agreed at its Nov. 15-16 meeting in Baltimore.
You may also be interested in...
MCAC Panel Recommends Medicare Coverage For Stem Cell Therapy
Autologous stem cell transplantation (ASCT) in combination with high dose chemotherapy should receive Medicare coverage for treatment of multiple myeloma, the Drugs, Biologics and Therapeutics Panel of the Medicare Coverage Advisory Committee unanimously recommended Sept. 16 in a 5-0 vote.
Medicare Coverage Advisory Committee Charter Calls For 12 Industry Reps
The Health Care Financing Administration's Medicare Coverage Advisory Committee will include 12 industry representatives and an equal number of consumer reps to serve as non-voting members of the 120-member counseling body, HCFA states in the committee charter released Dec. 29.
SPECT COINCIDENCE DETECTION EQUIPMENT ADDED TO FDG PET MEDICARE COVERAGE DECISION FOLLOWING ADAC PRESENTATION TO HCFA; INTERIM COVERAGE EFFECTIVE JAN. 1
Adac's eleventh-hour presentation of data on coincidence imaging cameras to the Health Care Financing Administration won the company coverage of the technology under the agency's expansion of Medicare reimbursement for positron emission tomography. The revised policy allows coverage of fluorodeoxyglucose PET and coincidence detection imaging for certain lung cancer scanning procedures .